Saturday, April 20, 2024
Canada’s Politics and Government News Source Since 1989
Saturday, April 20, 2024 | Latest Paper

Michael May

Michael May, PhD, is president and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian, not-for-profit that develops technologies, launches new companies and catalyzes investment in the field of regenerative medicine, including cell and gene therapy. 

Opinion | BY MICHAEL MAY, ALLISON BROWN | January 8, 2024
To shepherd breakthroughs, we need a framework that allows stakeholders to share research, development, manufacturing, and entrepreneurial expertise, write Michael May and Allison Brown. Photograph courtesy of the National Cancer Institute
Opinion | BY MICHAEL MAY, ALLISON BROWN | January 8, 2024
Opinion | BY MICHAEL MAY, ALLISON BROWN | January 8, 2024
To shepherd breakthroughs, we need a framework that allows stakeholders to share research, development, manufacturing, and entrepreneurial expertise, write Michael May and Allison Brown. Photograph courtesy of the National Cancer Institute
Opinion | BY MICHAEL MAY | September 13, 2021
Stainless steel bioreactors, pictured. It is encouraging and exciting that bio-manufacturing has become a priority of the Canadian life sciences enterprise, and it is understandable that recent investments have been driven by COVID-19 vaccine development and manufacturing, writes Michael May. Photograph courtesy of Commons Wikimedia/Rick Lawless
Opinion | BY MICHAEL MAY | September 13, 2021
Opinion | BY MICHAEL MAY | September 13, 2021
Stainless steel bioreactors, pictured. It is encouraging and exciting that bio-manufacturing has become a priority of the Canadian life sciences enterprise, and it is understandable that recent investments have been driven by COVID-19 vaccine development and manufacturing, writes Michael May. Photograph courtesy of Commons Wikimedia/Rick Lawless